Metastatic colorectal cancer in the elderly: An overview of the systemic treatment modalities (Review)

Oncology Letters

Volumn 2, Issue 1, 2011, Pages 3-11

  Stec, Rafał ^a   Bodnar, Lubomir ^a   Smoter, Marta ^a   Maczewski, Michał ^b   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Chemotherapy; Colorectal cancer; Efficacy; Elderly patients; Targeted therapies; Toxicity

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CELECOXIB; CETUXIMAB; CREATININE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG EMBOLISM; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NAIL TOXICITY; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; SKIN TOXICITY; STATISTICAL SIGNIFICANCE; STOMATITIS; SYSTEMIC THERAPY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; VOMITING; WEAKNESS;

EID: 78751513473     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2010.212     Document Type: Article

References (26)

1. Ries LAG, Eisner MP, Kosary CL, et al: SEER Cancer Statistics Review 1973-1998. National Cancer Institute, Bethesda, MD, 2001.
2. National Institutes of Health: Surveillance epidemiology and end results: Available at: http://seer.cancer.gov/, 2008.
3. Adjei AA: A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. J Clin Pharmacol: 48: 265-277, 1999.
4. Lichtman SM and Villani G: Chemotherapy in the elderly: phar4. macologic considerations. Cancer Control 7: 548-556, 2000.
5. Folprecht G, Seymour MT, Saltz L, et al: Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691patients in randomized controlled trials. J Clin Oncol 26: 1443-1451, 2008.
6. Feliu J, Escudero P, Llosa F, et al: Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group study. J Clin Oncol 23: 3104-3111, 2005.
7. Cassidy J, Twelves C, Van Cutsem E, et al: First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13: 566-575, 2002.
8. Ho C, Ng K, O'Reilly S and Gill S: Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis. Clin Colorectal Cancer 5: 279-282, 2005.
9. Jensen SA, Lonborg JT and Sorensen JB: Benefits and risk of palliative capecitabine-based therapy to elderly patients with advanced colorectal cancer: Danish single center experiences. Acta Oncol 45: 67-76, 2006.
10. Stec R, Bodnar Land Szczylik C: Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65years and older with advanced colorectal cancer: a retrospective analysis. JCancer Res Clin Oncol 136: 283-292, 2010.
11. Arkenau HT, Graeven U, Kubicka S, et al: Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. Clin Colorectal Cancer 7: 60-64, 2008.
12. Twelves CJ, Butts CA, Cassidy J, et al: Capecitabine/oxaliplatin, oxaliplatin a safe and active first-line regiment for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II Study. Clin Colorectal Cancer 5: 101-107, 2005.
13. Feliu J, Salud A, Escudero P, et al: XELOX (capecitabine plus oxaliplatin) as first-line treatment for patients over 70 years of age with advanced colorectal cancer. Br J Cancer 94: 969-975, 2006.
14. Tabah-Fisch I, Maindrault-Goebel F, Benavides M, et al: Oxaliplatin/5 FU/LV is feasible, safe and active in elderly colorectal cancer (CRC) patients. ASCO abs. 556, 2002.
15. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al: Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/lecovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24: 4085-4091, 2006.
16. Bruce C, Köhne C.-H. and Audisio R.A: Treatment of advanced colorectal cancer in the elderly. Eur J Surg Oncol: 84-87, 2007.
17. Jackson NA, Barrueco J, Soufi-Mahjoubi R., et al: Comparing safety and efficacy of first-line irinitecan/fluorropyrimidine combinations in eldery versus nonelderly patients with metastatic colorectal cancer. Cancer 115: 2617-2629, 2009.
18. Gràvalos C, River F, Massuti B, et al: Cetuximab and capecitabine as first-line treatment for elderly patient (pts) with metastatic colorectal cancer (mCRC): preliminary results of TTDtrial. (suppl) J Clin Oncol 26, 2008.
19. Sastre J, Aranda E, Gràvalos C, et al: First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol: Dec. 28, 2009 (Epub ahead of print).
20. Hecht JR, Mitchell E, Chidiac T, et al: A randomized phase IIIBtrial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27: 672-680, 2009.
21. Wolpin BM and Mayer RJ: Systemic treatment of colorectal 21. cancer. Gastroenterology 134: 1296-1310, 2008.
22. Saltz L, Clarke S, Diaz-Rubio E, et al: Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first line metastatic colorectal cancer. J Clin Oncol 25: 18S, 2007.
23. Sama A, Gonsalves W, Aldoss I, et al: Adjuvant chemotherapy for colon cancer patients age 80 and older: Veteran's Affairs Central Cancer (VACCR) database analysis. Gastrointestinal Cancers Symposium ASCO abs. 450, 2010.
24. Köhne C-H, Folprecht G, Goldberg RM, et al: Chemotherapy in elderly patients with colorectal cancer. Oncologist 13: 390-402, 2008.
25. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008.
26. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl Med 359: 1757-1765, 2008.